Sign in Subscribe
COVID-19

Coadministering Vaccines Enhances COVID-19 Vaccination Uptake in Adults

Strategic Insights

— 1 min read

New research conducted at Copenhagen University Hospital in Hillerod, Denmark, has found that coadministering vaccines can significantly enhance COVID-19 vaccination uptake in adults. Despite the potential benefits of this practice, there was limited data supporting its effectiveness. The study involved 3104 adults who received a fourth dose of the COVID-19 vaccine, either alone or coadministered with influenza and pneumococcal vaccines, from January to December 2022.

Key Takeaways:

  • The study found that coadministering vaccines can effectively enhance COVID-19 vaccination uptake in adults, with a median age of 70 years and 54% of participants being female.
  • The adjusted odds of a 2-fold anti-spike IgG geometric mean fold rise (GMFR) were 0.64 (P < 0.001) in the COVID-19 + influenza group, indicating a significant improvement in immunogenicity.
  • The study concluded that coadministering vaccines is supported by the recommendation for vaccine coadministration in adults, based on the findings of the research.
  • The research team involved in this study includes Omid Rezahosseini, Copenhagen University Hospital, Hana Khajeh Rahimi, Nikoline Erland Jensen, Zitta Barrella Harboe, Jens Ulrik Staehr Jensen, Sisse Rye Ostrowski, Jens Lundgren, Charlotte Svaerke Jorgensen, Thea K. Fischer, and Lars Ostergaard.
  • The study provides evidence for the effectiveness of coadministering vaccines in enhancing COVID-19 vaccination uptake in adults, which can inform public health policies and practices.

Statistics:

  • 3104 adults participated in the study, with a median age of 70 years (interquartile range: 60-77).
  • 1670 (54%) of participants were female.
  • The adjusted odds of a 2-fold anti-spike IgG GMFR were 0.64 (P < 0.001) in the COVID-19 + influenza group.
  • The anti-spike IgG geometric mean fold rise (GMFR) values were 1.95, 1.56, and 1.42 in the COVID-19, COVID-19 + influenza, and COVID-19 + influenza + pneumococcal vaccine groups, respectively.

Sources:

  • NewsRx. Investigators at Copenhagen University Hospital Detail Findings in COVID-19 (Immunogenicity and Safety of the Coronavirus Disease 2019 Messenger Rna Vaccine Coadministered With Influenza and 23-valent Pneumococcal Polysaccharide Vaccines). Biotech Week. October 15, 2025; p 279.
  • Omid Rezahosseini, Hana Khajeh Rahimi, Nikoline Erland Jensen, Zitta Barrella Harboe, Jens Ulrik Staehr Jensen, Sisse Rye Ostrowski, Jens Lundgren, Charlotte Svaerke Jorgensen, Thea K. Fischer, and Lars Ostergaard. Immunogenicity and Safety of the Coronavirus Disease 2019 Messenger Rna Vaccine Coadministered With Influenza and 23-valent Pneumococcal Polysaccharide Vaccines. Clinical Infectious Diseases, 2025.

Read more